-
06:38:04 PM

INCY Stock News

03/22/23 1:14 PM
Nasdaq : INCY
fda approval
Incyte Announces FDA Approval of Zynyz™ (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)
Incyte today announced that the U.S. Food and Drug Administration has approved Zynyz™, a humanized monoclonal antibody targeting programmed death receptor-1, for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The Biologics License Application for Zynyz for this indication has been approved under...
RHEA-AI
neutral
03/18/23 3:40 PM
Nasdaq : INCY
clinical trial
Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
Incyte today announced new data from a Phase 2 b clinical trial evaluating the safety and efficacy of povorcitinib, an investigational oral JAK1 inhibitor, in adult patients with extensive nonsegmental vitiligo. These data were presented today in a late-breaking oral presentation at the 2023 American Academy of Dermatology Annual Meeting, held from March...
RHEA-AI
positive
03/18/23 10:40 AM
Nasdaq : INCY
clinical trial
Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura® (Ruxolitinib) Cream in Vitiligo
Incyte today announced new 104- week results from the pivotal Phase 3 TRuE-V clinical trial program evaluating Opzelura ® cream 1.5% in patients 12 years of age and older with nonsegmental vitiligo, a chronic autoimmune disease characterized by depigmentation of skin. These data were presented today in two late-breaking oral presentations at the 2023...
RHEA-AI
neutral
03/14/23 6:30 PM
Nasdaq : INCY
Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023
Incyte today announced that multiple abstracts from across its oncology portfolio will be presented during the upcoming American Association for Cancer Research Annual Meeting 2023, held April 14-19, in Orlando, Florida. “As Incyte continues to advance research in areas where we believe we can have the biggest impact for patients, we look forward to sharing...
RHEA-AI
neutral
03/07/23 6:30 AM
Nasdaq : INCY
partnership
Caris Life Sciences and Incyte Enter Into Broad Precision Medicine Partnership to Advance Incyte's Oncology Pipeline
Caris Life Sciences ®, the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, today announced a strategic research partnership with Incyte Corporation to augment precision medicine approaches for Incyte's oncology pipeline. "This partnership with Incyte will...
RHEA-AI
very positive
03/06/23 12:23 PM
Nasdaq : INCY
Multiple Abstracts from Incyte’s Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting
Incyte today announced that multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2023 American Academy of Dermatology Annual Meeting, held March 17-21, 2023, in New Orleans. “The research being featured at this year’ s AAD Annual Meeting highlights the potential of Incyte therapies to meet the needs of patients...
RHEA-AI
neutral
03/03/23 4:35 PM
Nasdaq : INCY
clinical trial
Incyte Provides Update on Interim Analysis of Phase 3 LIMBER-304 Study of Parsaclisib and Ruxolitinib in Patients with Myelofibrosis
Incyte today announced that it will discontinue the Phase 3 LIMBER-304 trial following results of a pre-planned interim analysis conducted by an independent data monitoring committee indicating that the study is unlikely to meet the primary endpoint in the intent-to-treat patient population. While further review of the data is conducted, Incyte will...
RHEA-AI
neutral
02/24/23 7:07 AM
Nasdaq : INCY
Incyte Announces Positive CHMP Opinion for Ruxolitinib Cream (Opzelura™) for the Treatment of Non-segmental Vitiligo in Adults and Adolescents
Incyte today announced that the European Medicines Agency Committee for Medicinal Products for Human Use has issued a positive opinion recommending the approval of ruxolitinib cream for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. “The positive CHMP opinion brings us one step closer to...
RHEA-AI
positive
02/10/23 8:20 AM
Nasdaq : INCY
clinical trial
Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa
Incyte today announced new 52- week results from a Phase 2 study evaluating the efficacy and safety of povorcitinib, an oral JAK1 inhibitor, in adult patients with hidradenitis suppurativa. These data were presented as an oral presentation at the 12th Conference of the European Hidradenitis Suppurativa Foundation, held from February 8-10, 2023, in Florence,...
RHEA-AI
neutral